Mosaic Immunoengineering INC 10-Q quarterly reports

Mosaic ImmunoEngineering reports a critically low cash balance and substantial accumulated deficit, raising significant doubts about its ability to continue operations without immediate additional funding.

Mosaic ImmunoEngineering, Inc. reported its first-quarter 2026 financial results, highlighting a significant decrease in cash and cash equivalents and continued operational losses, underscoring the critical need for future capital raises.

Mosaic ImmunoEngineering, a development-stage biotech, reported significant cash depletion and a going concern warning, with a key acquisition agreement expiring and multiple board resignations.

Mosaic ImmunoEngineering, a development-stage biotech, reported significant financial challenges, including a going concern warning and the expiration of a key acquisition agreement.

Mosaic ImmunoEngineering's Q1 2025 report reveals a net loss of $181,320 and raises concerns about the company's ability to continue as a going concern due to limited cash and the need for additional financing.

Mosaic ImmunoEngineering's Q3 2024 report reveals ongoing losses and significant financial challenges, raising substantial doubt about the company's ability to continue as a going concern.

Mosaic ImmunoEngineering faces significant financial challenges and is exploring a potential acquisition to bolster its pipeline.

Mosaic ImmunoEngineering's Q1 2024 report reveals ongoing financial challenges and a strategic pivot towards acquiring new technologies from Oncotelic Therapeutics.